News | Study Suggests Anti-Müllerian Hormone May Drive Ovulatory Dysfunction in PCOS
Anti-Müllerian Hormone (AMH) has traditionally been viewed as a byproduct of polycystic ovary syndrome (PCOS), used only to indicate the number of ovarian follicles. New preclinical research from Weill Cornell Medicine suggests that AMH may be more than a passive marker and could actively contribute to the condition, causing ovulatory dysfunction and affecting fertility.
AMH May Accelerate Follicle "Overmaturation"
During a normal cycle, ovarian follicles provide an environment in which oocytes grow. As a follicle matures, it releases an egg that can be fertilized. In people with PCOS, however, the ovaries contain many small follicles that fail to continue maturing and ovulate. These follicles produce high levels of AMH.
Study leader Dr. Daylon James, Associate Professor of Stem Cell Biology in the Department of Obstetrics and Gynecology and Reproductive Medicine at Weill Cornell Medicine, said there had previously been no evidence that high AMH levels were harmful in themselves. This study is the first to show that AMH may disrupt the coordinated development of follicles and oocytes, causing premature luteinization. In other words, the cells in the follicle's outer layer become "overcooked" while the oocyte inside remains immature.
Dr. James explained, "It is like having the oven temperature too high—the outside is overcooked while the inside is not ready."
Distinctive Experimental Design Reveals the Mechanism
To investigate the direct effects of AMH, the research team used a human ovarian xenograft model by transplanting human ovarian tissue into immunodeficient mice. One group received both ovarian tissue and cells that continuously secreted AMH, while the control group received only ovarian tissue.
Lead author Dr. Limor Man said, "This design allowed tissue from the same donor to be used in both the experimental and control groups, minimizing the effects of genetic background and differences in other hormone levels. It provided an ideal comparison."
Human ovarian tissue exposed to high AMH levels developed features of late-stage follicular maturation prematurely, confirming AMH's key role in abnormal follicle development.
Reinterpreting PCOS Pathology
The numerous small follicles in PCOS ovaries have long been considered "arrested." Dr. Man said the new data suggest that these small follicles are not static. Instead, they are continually produced, mature too quickly, and then fail, ultimately preventing ovulation. This new understanding helps explain the persistent ovulatory dysfunction and infertility associated with PCOS.
Clinical and Therapeutic Implications
PCOS affects about 10% of women of reproductive age worldwide. In addition to infertility, it is associated with hyperandrogenism, including excess body hair, metabolic abnormalities, increased diabetes risk, and greater susceptibility to endometrial cancer. Most current treatments address symptoms only, and the condition often persists beyond menopause.
Dr. James said that drugs targeting the AMH pathway may potentially restore ovulatory cycles and improve other PCOS symptoms.
The study deepens understanding of the mechanisms underlying PCOS and offers a new direction for future precision treatments.
News | Study Suggests Anti-Müllerian Hormone May Drive Ovulatory Dysfunction in PCOS
News | Study Suggests Anti-Müllerian Hormone May Drive Ovulatory Dysfunction in PCOS
Anti-Müllerian Hormone (AMH) has traditionally been viewed as a byproduct of polycystic ovary syndrome (PCOS), used only to indicate the number of ovarian follicles. New preclinical research from Weill Cornell Medicine suggests that AMH may be more than a passive marker and could actively contribute to the condition, causing ovulatory dysfunction and affecting fertility.
AMH May Accelerate Follicle "Overmaturation"
During a normal cycle, ovarian follicles provide an environment in which oocytes grow. As a follicle matures, it releases an egg that can be fertilized. In people with PCOS, however, the ovaries contain many small follicles that fail to continue maturing and ovulate. These follicles produce high levels of AMH.
Study leader Dr. Daylon James, Associate Professor of Stem Cell Biology in the Department of Obstetrics and Gynecology and Reproductive Medicine at Weill Cornell Medicine, said there had previously been no evidence that high AMH levels were harmful in themselves. This study is the first to show that AMH may disrupt the coordinated development of follicles and oocytes, causing premature luteinization. In other words, the cells in the follicle's outer layer become "overcooked" while the oocyte inside remains immature.
Dr. James explained, "It is like having the oven temperature too high—the outside is overcooked while the inside is not ready."
Distinctive Experimental Design Reveals the Mechanism
To investigate the direct effects of AMH, the research team used a human ovarian xenograft model by transplanting human ovarian tissue into immunodeficient mice. One group received both ovarian tissue and cells that continuously secreted AMH, while the control group received only ovarian tissue.
Lead author Dr. Limor Man said, "This design allowed tissue from the same donor to be used in both the experimental and control groups, minimizing the effects of genetic background and differences in other hormone levels. It provided an ideal comparison."
Human ovarian tissue exposed to high AMH levels developed features of late-stage follicular maturation prematurely, confirming AMH's key role in abnormal follicle development.
Reinterpreting PCOS Pathology
The numerous small follicles in PCOS ovaries have long been considered "arrested." Dr. Man said the new data suggest that these small follicles are not static. Instead, they are continually produced, mature too quickly, and then fail, ultimately preventing ovulation. This new understanding helps explain the persistent ovulatory dysfunction and infertility associated with PCOS.
Clinical and Therapeutic Implications
PCOS affects about 10% of women of reproductive age worldwide. In addition to infertility, it is associated with hyperandrogenism, including excess body hair, metabolic abnormalities, increased diabetes risk, and greater susceptibility to endometrial cancer. Most current treatments address symptoms only, and the condition often persists beyond menopause.
Dr. James said that drugs targeting the AMH pathway may potentially restore ovulatory cycles and improve other PCOS symptoms.
The study deepens understanding of the mechanisms underlying PCOS and offers a new direction for future precision treatments.
Source:
Compiled from online sources